Early Efficacy Data Reported from First TNBC Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in CTCs in Ph 1b Trial July 15, 2025
Bria-IMT Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer July 15, 2025
Results from Ph 1/2 Study of Sacituzumab Tirumotecan (sac-TMT) in Solid Tumors Refractory to Standard Therapies Published in Journal of Hematology & Oncology June 17, 2025
FDA authorizes Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers June 17, 2025
Trodelvy Demonstrates Significant PFS Improvement in 1L Metastatic TNBC Patients Not Candidates for Checkpoint Inhibitors in ASCENT-03 trial May 27, 2025
IND application submitted to the U.S. FDA for UTRxM1-18 for targeting c-MYC driven cancers May 13, 2025
Second Interim Analysis of OBI-822 Ph 3 Trial Completed and Trial Termination announced April 30, 2025
Trodelvy + Keytruda Demonstrate Statistically Significant PFS Improvement in Patients With 1L PD-L1+ Metastatic TNBC April 30, 2025
Trodelvy + Keytruda Demonstrated PFS Improvement in Patients With Previously Untreated PD-L1+ Metastatic TNBC April 22, 2025
First Patient Dosed in the WIN-B Trial of Debio 0123 & Trodelvy® in Advanced Breast Cancer March 3, 2025
Positive Initial Clinical Data from Ph 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660) Announced; Expansion in TNBC Initiated January 15, 2025
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on PYX-201 program December 26, 2024
Nadunolimab clinical trials in AML/MDA and TNBC to be initiated in Q4 2024 and H2 2025, respectively September 3, 2024
FAILED TRIAL: Ph 3 PRESERVE 2 Trial of Trilaciclib Before 1L chemo in mTNBC did Not Achieve Statistical Significance in the Primary Endpoint of OS July 1, 2024
